NovoCure Limited (NVCR)
NASDAQ: NVCRHealth CareMedical/Dental InstrumentsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NVCR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.25B
- EPS (TTM)
- -$1.06
- Dividend yield
- None
- 52-week range
- 9.82 – 21.45
- Day range
- 10.61 – 11.06
- Volume / Avg
- 1.64M / 1.51M
- Beta
- —
- Shares outstanding
- 116.92M
52-week range
NVCR stock today
Shares of NovoCure (NVCR) finished higher on Nov 20 at $10.71, a gain of 0.19% or $0.02 per share, versus the S&P 500's 3.70% decline. Shares are 50.1% below their 52-week high of $21.45, set on Jul 24, 2026 and 9.1% above the 52-week low of $9.82, near the bottom of the past year's range. NVCR is down 17.2% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 10.4%.
NovoCure has posted a net loss over the last twelve months (EPS of -$1.06), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About NovoCure
Company profileNovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer.
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- CEO
- Mr. Frank Leonard
- Headquarters
- Baar
- Employees
- 1,605
- IPO year
- 2015
- Website
- novocure.com
Financial highlights
Full financialsIn fiscal 2025, NovoCure generated $655.4 million in revenue, up 8.3% from fiscal 2024, its 2nd consecutive year of revenue growth. NovoCure reported a net loss of $136.2 million, compared with a loss of $168.6 million a year earlier. Gross margin was 74.5% (down from 77.3%) and operating margin -23.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $655.35M | $605.22M | $509.34M | $537.84M | $535.03M |
| Growth | +8.28% | +18.82% | -5.30% | +0.53% | +8.23% |
| Net income | $-136.23M | $-168.63M | $-207.04M | $-92.53M | $-58.35M |
| EPS (diluted) | $-1.22 | $-1.56 | $-1.95 | $-0.88 | $-0.56 |
Analyst forecast
ForecastConsensus (7 analysts)
buy
Avg. price target
$26.14+144.07%
- Strong buy 1
- Buy 3
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Oct 29, 2026
- EPS actual vs est.
- $-0.09 vs $-0.21
- Surprise
- +57.14%
NVCR news
All NVCR news- FDA Rejects NovoCure’s Optune Mya for Lung Cancer Brain Metastases. Here's What It Means for Investors.Nasdaq
- NovoCure denied FDA approval of Optune Mya for brain metastasesSeeking Alpha
- FDA Cites Uncertainty Over Clinical Benefit In Novocure's Optune Mya Application; Stock DownNasdaqNVCR, MOG.B
- NovoCure: 3 Key Takeaways for Long-Term InvestorsNasdaq
- Novocure outlines 2026 net revenue of $736M-$743M as it updates adjusted EBITDA to $24M-$34MSeeking Alpha
- NovoCure slips despite quarterly beats, updated guidanceSeeking Alpha
- NovoCure Limited Reports Third Quarter 2026 Financial Results and Raises 2026 GuidanceNasdaqNVCR, HEI.A
- NovoCure Q3 Loss DecreasesNasdaqNVCR, SUN
NovoCure peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TNDMTandem Diabetes Care Inc. | 17.46 | +3.93% | $1.22B | vs NVCR |
| DRTSAlpha Tau Medical Ltd. | 11.76 | +3.93% | $1.09B | vs NVCR |
| PRCTPROCEPT BioRobotics Corporation | 24.70 | -4.08% | $1.42B | vs NVCR |
| SIBNSI-BONE Inc. | 23.73 | -0.08% | $1.07B | vs NVCR |
| IRMDiRadimed Corporation | 81.02 | -0.30% | $1.04B | vs NVCR |
| IARTIntegra LifeSciences Holdings Corporation | 13.25 | -2.21% | $1.03B | vs NVCR |
| ATECAlphatec Holdings Inc. | 6.68 | -3.19% | $1.02B | vs NVCR |
| SGPSpyGlass Pharma Inc. | 30.43 | -1.14% | $1.02B | vs NVCR |
Indexes, lists and sector
NovoCure stock FAQ
What is NovoCure's stock price today?
NVCR last traded at $10.71 as of Nov 20, 4:00 PM EST, up 0.19% on the day. Prices are delayed at least 15 minutes.
Who is NovoCure's CEO?
Mr. Frank Leonard is the chief executive officer of NovoCure Limited, which has about 1,605 employees.
What is the NVCR 52-week high?
The 52-week high for NVCR is $21.45 and the 52-week low is $9.82. The stock is currently 50.1% below its high.